Table 3.

Association of Rituximab and Hypogammaglobulinemia With Infections

	Serious infections				Recurrent outpatient infections
	Crude HR		Adjusted HR		Crude HR		Adjusted HR
	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value
Cumulative dose (ref ≤2 g)
>2 and ≤4 g	1.48 (1.01–2.16)	0.0432	1.27 (0.87–1.85)	0.2249	1.54 (1.34–1.76)	<0.0001	1.55 (1.35–1.77)	<0.0001
>4 g	2.36 (1.66–3.36)	<0.0001	1.56 (1.09–2.24)	0.0162	1.82 (1.54–2.14)	<0.0001	1.73 (1.44–2.06)	<0.0001
Serum IgG level (ref ≥700 mg/dL)
≥500 and <700 mg/dL	1.93 (1.23–3.02)	0.0042	1.60 (1.05–2.42)	0.0279	1.31 (1.02–1.67)	0.0328	1.19 (0.93–1.53)	0.1611
<500 mg/dL	4.01 (2.06–7.82)	<0.0001	2.98 (1.56–5.72)	0.0010	2.50 (1.80–3.46)	<0.0001	2.06 (1.52–2.80)	<0.0001
Age per 10 y	1.32 (1.16–1.51)	<0.0001	1.06 (0.92–1.22)	0.4506	1.05 (0.99–1.12)	0.1277	1.01 (0.94–1.08)	0.8380
Race and ethnicity (ref = White)
Black, API, Hispanic, or Other/Unk	0.81 (0.57–1.14)	0.2319	—	—	1.04 (0.89–1.22)	0.6283	—	—
Female sex	0.57 (0.40–0.82)	0.0020	0.53 (0.38–0.75)	0.0003	1.91 (1.53–2.37)	<0.0001	1.90 (1.53–2.35)	<0.0001
Advanced disability	6.12 (4.31–8.71)	<0.0001	5.51 (3.71–8.18)	<0.0001	1.40 (1.20–1.62)	<0.0001	1.24 (1.06–1.44)	0.0062
Prior DMT use (ref = none)
Highly effective	0.91 (0.57–1.44)	0.6843	—	—	1.38 (1.12–1.71)	0.0024	1.17 (0.95–1.44)	0.1435
Modestly effective	0.97 (0.65–1.47)	0.8984	—	—	1.15 (0.96–1.38)	0.1206	1.03 (0.86–1.22)	0.7613
Diabetes	1.46 (0.88–2.43)	0.1425	1.15 (0.72–1.84)	0.5588	1.16 (0.92–1.47)	0.2197	—	—
COPD	0.94 (0.47–1.90)	0.8684	—	—	1.58 (1.26–1.97)	<0.0001	1.68 (1.34–2.11)	<0.0001
Obesity	0.80 (0.55–1.15)	0.2213	—	—	1.28 (1.10–1.48)	0.0010	1.25 (1.09–1.45)	0.0021

Abbreviations: API = Asian/Pacific Islander; COPD = chronic obstructive pulmonary disease; DMT = disease-modifying therapy; HR = hazard ratio; IgG = immunoglobulin G; Unk = unknown.